Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan Adds Accretive Aesthetics Assets In $2.9bn LifeCell Acquisition

Executive Summary

Allergan will pay $2.9bn in cash for LifeCell, a division of Acelity, adding its first regenerative medicine portfolio and marking its first commercial-stage deal in more than a year. The company hopes to exploit the surgical products for aesthetic uses beyond breast reconstruction.


Related Content

Scrip Asks… What's The Current Climate For Deal-Making? (Part 1)
Allergan Pays $2bn-Plus For Zeltiq, Expanding Aesthetics Business
Allergan Confident About Continued Growth, Swats Down Competition Concerns
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Allergan's Fishing For Deals, But Don't Expect A Big Catch
Allergan Bolsters Blockbuster Botox With Topical Toxin Buy
Kybella Approval Shows How To Work With FDA On Clinical Outcome Assessments
Allergan buys chin fat firm Kythera for $2.1bn
Acellular Dermal Matrices: The New Standard In Breast Reconstruction
Kinetic seals $1.7bn deal with LifeCell and tags on new biosurgery division


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts